KM Research Hub

FIXED FIVE-YEAR COHORT AUDIT

近五年文献重新检索与对照

旧查询复现与严格 v3 为主比较;历史库存和广召回仅用于解释差异与检查漏检。

complete · complete 汇总 CSV 明细 CSV
固定日期2021-07-29 至 2026-07-29
入排版本oncology-definitive-rct-km-v3
并集论文20925
批次键five-year-20210729-20260729-v1

四个独立队列

数字为批次中保存的原始 PMID 数,不会随着日常监测改变。

历史库存参照组 13065 audit_reference · server-inventory-snapshot-v1
旧查询复现组 7069 primary_legacy · legacy-phase3-fulltext-v1
严格 v3 主组 4707 primary_new · oncology-phase3-survival-strict-v3
v3 广召回影子组 13640 recall_audit · oncology-phase3-survival-discovery-v3

集合关系

交集和差集均按 PMID 精确计算;DOI 只用于明细核对。

比较交集左组独有右组独有
历史库存 ↔ 旧查询复现 7028 6037 41
旧查询复现 ↔ 严格 v3 2464 4605 2243
严格 v3 ↔ 广召回影子组 4707 0 8933
严格查询未命中、但影子组经 v3 筛选后合格 166 篇

元数据入排

20925 / 20925 已完成

KM 证据

仅检查 v3 元数据合格论文,不运行曲线数字化。

论文明细

共 8933 篇;可组合筛选集合关系、入排结果和 KM 证据。

论文队列集合关系v3 入排KM 证据
Risk factors and novel predictive model for metastatic cutaneous squamous cell carcinoma: a population-based analysis. PMID 37039868 · Arch Dermatol Res · 2023-Oct Retrospective population-based database analysis (SEER) for prognostic model development, not a report of a Phase II/III or Phase III/IIIb randomized trial with a drug intervention. The publication type 'Randomized Controlled Trial' appears to be a misclassification by PubMed metadata, as the abstract describes a retrospective study.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Detailed Evaluation of the Effect of Prostate-specific Antigen-based Screening on Morbidity and Mortality of Prostate Cancer: 21-year Follow-up Results of the Rotterdam Section of the European Randomised Study of Screening for Prostate Cancer. PMID 37029074 · Eur Urol · 2023-Oct The study is an eligible randomized controlled trial with a time-to-event endpoint (prostate cancer-specific mortality), but it evaluates a screening intervention (PSA-based screening) rather than a drug-containing intervention for cancer treatment. Therefore, it does not meet the inclusion criteria for a drug-containing intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Low levels of WRAP53 predict decreased efficacy of radiotherapy and are prognostic for local recurrence and death from breast cancer: a long-term follow-up of the SweBCG91RT randomized trial. PMID 36975842 · Mol Oncol · 2023-Oct The study is a secondary/prognostic analysis of a biomarker (WRAP53) within a randomized trial of radiotherapy in breast cancer. It does not meet the core requirement of a drug-containing intervention. The trial phase is not explicitly stated in the provided metadata as Phase III/IIIb or Phase II/III.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
The clinical effect of modified slow Mohs circular skin biopsy on penoscrotal extramammary Paget's disease. PMID 36737341 · Asian J Surg · 2023-Oct The study is a randomized trial in human oncology but is ineligible because it lacks a drug intervention and does not report a time-to-event efficacy endpoint. It is a surgical technique comparison.
B
仅广召回影子组 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
Arthralgia induced by endocrine therapy with or without cyclin-dependent kinase 4/6 inhibitors in breast cancer: A systematic review and meta-analysis. PMID 36085411 · Asia Pac J Clin Oncol · 2023-Oct 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
The Impact of Trimetazidine on Cardiac Fibrosis, Inflammation, and Function in Ischemic Cardiomyopathy Patients. PMID 35538296 · Cardiovasc Drugs Ther · 2023-Oct The study is a randomized controlled trial of a drug (Trimetazidine) in humans with primary results, but it is not an oncology study (focused on ischemic cardiomyopathy, not malignant neoplasm) and does not report a time-to-event efficacy endpoint (OS, PFS, DFS, EFS, RFS, TTP, etc.).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Effect of exercise on body composition among women with ovarian cancer. PMID 35377104 · J Cancer Surviv · 2023-Oct The study is excluded because it does not involve a drug intervention or a time-to-event efficacy endpoint. The primary endpoint is body composition change, and the intervention is exercise, not a drug. The phase of the trial is not specified in the metadata.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Comparison of Narrative Video and Flipchart Presentation to Promote Cervical Cancer Screening Among Latinas Along the Border. PMID 35112582 · Health Educ Behav · 2023-Oct The study is a randomized, human, oncology-related (cervical cancer screening) health promotion trial with original results. However, it is excluded because it lacks a drug-containing intervention (uses educational tools only) and a primary/key time-to-event efficacy endpoint (the primary outcome is screening completion, a binary categorical outcome, not a time-to-event measure like OS/PFS). Phase is not specified but is not relevant given the other exclusions.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Early palliative care and quality of dying and death in patients with advanced cancer. PMID 33619220 · BMJ Support Palliat Care · 2023-Oct The study is a randomized trial in oncology (advanced cancer) but is excluded because it does not meet the required criteria: it is not a Phase III/IIIb or Phase II/III trial (phase is not specified, but it is a cluster-randomized trial of palliative care, not a drug trial), it does not have a drug-containing intervention (the intervention is early palliative care), and it does not have a primary/time-to-event efficacy endpoint (the endpoints are quality of dying and death and quality of life at end of life, which are patient-reported outcome measures, not time-to-event outcomes like OS or PFS). The study is also categorized as a secondary analysis within the trial, focusing on specific outcomes rather than primary efficacy.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
RELAY phase 3 randomized study: a step closer to the clinic for ctDNA in non-small cell lung cancer treatment monitoring? PMID 38090513 · Transl Lung Cancer Res · 2023-Nov-30 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Preoperative dexamethasone administration in hepatectomy of 25-min intermittent Pringle's maneuver for hepatocellular carcinoma: protocol for a randomized controlled trial. PMID 38037035 · Trials · 2023-Nov-30 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Quality assurance in a phase III, multicenter, randomized trial of POstmastectomy radioThErapy in Node posiTive breast cancer with or without Internal mAmmary nodaL irradiation (POTENTIAL): a planning benchmark case. PMID 38031125 · Radiat Oncol · 2023-Nov-29 This is a planning benchmark case report for a phase III randomized trial evaluating radiotherapy (internal mammary nodal irradiation) in breast cancer. It reports on radiation plan quality and protocol compliance, not on a time-to-event efficacy endpoint like OS or PFS. While it is from a randomized, phase III oncology trial, it lacks a drug-containing intervention and a primary time-to-event efficacy endpoint, making it ineligible.
H L B
旧查询独有 needs_reviewmodel_uncertain pending 0 Figure · 0 Panel · risk -
A pilot study of multi-antigen stimulated cell therapy-I plus camrelizumab and apatinib in patients with advanced bone and soft-tissue sarcomas. PMID 38031088 · BMC Med · 2023-Nov-29 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
REstrictive versus StandarD FlUid Management in Mechanically Ventilated ChildrEn Admitted to PICU: study protocol for a pilot randomised controlled trial (REDUCE-1). PMID 38030251 · BMJ Open · 2023-Nov-29 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
HMG CoA reductase inhibitors (statins) for people with chronic kidney disease not requiring dialysis. PMID 38018702 · Cochrane Database Syst Rev · 2023-Nov-29 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Randomized, open-label, phase II, biomarker study of immune-mediated mechanism of action of neoadjuvant subcutaneous trastuzumab in patients with locally advanced, inflammatory, or early HER2-positive breast cancer-Immun-HER trial (GOIRC-01-2016). PMID 38016718 · J Immunother Cancer · 2023-Nov-28 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Results of a cluster randomized trial testing the Systems Analysis and Improvement Approach to increase cervical cancer screening in family planning clinics in Mombasa County, Kenya. PMID 38012647 · Implement Sci · 2023-Nov-27 The study is a randomized trial on cervical cancer screening but does not meet the core eligibility criteria: it lacks a drug-containing intervention and uses a screening prevalence ratio as the primary endpoint, not a time-to-event efficacy endpoint (e.g., OS, PFS). Phase is not specified.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Protocol for the EACH trial: a multicentre phase II study evaluating the safety and antitumour activity of the combination of avelumab, an anti-PD-L1 agent, and cetuximab, as any line treatment for patients with recurrent/metastatic head and neck squamous cell cancer (HNSCC) in the UK. PMID 38011968 · BMJ Open · 2023-Nov-27 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Evolution of the Management of Brain Metastases: A Bibliometric Analysis. PMID 38067273 · Cancers (Basel) · 2023-Nov-24 记录类型属于综述、Meta 分析、社论、评论、病例或指南。
H B
仅广召回影子组 excludedexcluded_publication_type pending 0 Figure · 0 Panel · risk -
Endoluminal radiofrequency ablation in patients with malignant biliary obstruction: a randomised trial. PMID 37652677 · Gut · 2023-Nov-24 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Evaluating niraparib versus active symptom control in patients with previously treated mesothelioma (NERO): a study protocol for a multicentre, randomised, two-arm, open-label phase II trial in UK secondary care centres. PMID 37993149 · BMJ Open · 2023-Nov-22 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
A Whole Food, Plant-Based Randomized Controlled Trial in Metastatic Breast Cancer: Feasibility, Nutrient, and Patient-Reported Outcomes. PMID 38045318 · Res Sq · 2023-Nov-21 The record is a randomized trial in human metastatic breast cancer with original results, but it does not meet the key eligibility criteria: (1) it is not a drug-containing intervention (it is a dietary intervention), and (2) its primary endpoint is patient-reported quality of life, not a time-to-event efficacy endpoint. The phase is not specified as Phase II/III or III/IIIb, but that is not the primary reason for exclusion.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Stem cell collection after lenalidomide, bortezomib and dexamethasone plus elotuzumab or isatuximab in newly diagnosed multiple myeloma patients: a single centre experience from the GMMG-HD6 and -HD7 trials. PMID 37990162 · BMC Cancer · 2023-Nov-21 The study is a randomized Phase III trial in oncology with drug intervention, but the primary endpoint is peripheral blood stem cell mobilization and collection, not a time-to-event efficacy endpoint (OS, PFS, DFS, etc.). It is a secondary analysis of a secondary endpoint, not the primary efficacy report of the trial.
H L B
旧查询独有 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Edoxaban for 12 Months Versus 3 Months in Patients With Cancer With Isolated Distal Deep Vein Thrombosis (ONCO DVT Study): An Open-Label, Multicenter, Randomized Clinical Trial. PMID 37638968 · Circulation · 2023-Nov-21 The study is a randomized, open-label, multicenter trial in cancer patients with a drug intervention (edoxaban) and reports an original result for a primary endpoint. However, it is not explicitly identified as a Phase III/IIIb or Phase II/III trial, and the primary endpoint is not a time-to-event efficacy endpoint (e.g., OS, PFS) analyzed via Kaplan-Meier or hazard ratio; instead, it is a composite endpoint reported as proportions and odds ratios at a fixed time point (12 months).
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Diagnosis of primary clear cell carcinoma of the liver based on Faster region-based convolutional neural network. PMID 37882066 · Chin Med J (Engl) · 2023-Nov-20 The study is an oncology randomized diagnostic evaluation of a deep learning model for distinguishing liver cancer subtypes. It is not a drug efficacy trial, lacks a drug intervention, and does not report any time-to-event efficacy endpoint.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Impact of BMI in Patients With Early Hormone Receptor-Positive Breast Cancer Receiving Endocrine Therapy With or Without Palbociclib in the PALLAS Trial. PMID 37556775 · J Clin Oncol · 2023-Nov-20 The record is a randomized, drug-intervention oncology trial with a time-to-event efficacy endpoint. However, the phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata (title, abstract, publication types, MeSH terms). The deterministic review flagged this as unclear. The report is a secondary analysis (preplanned by BMI subgroup) with efficacy results described as early follow-up, not the primary trial report.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular Lymphoma. PMID 37506346 · J Clin Oncol · 2023-Nov-20 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Subthreshold opioid use disorder prevention (STOP) trial: a cluster randomized clinical trial: study design and methods. PMID 37980494 · Addict Sci Clin Pract · 2023-Nov-18 The study is not in oncology, does not involve a drug-containing intervention, does not have a time-to-event efficacy endpoint, and is a trial protocol without results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Identification and verification of m6A-related miRNAs correlated with prognosis and immune microenvironment in colorectal cancer. PMID 37986290 · Medicine (Baltimore) · 2023-Nov-17 The record describes a retrospective, computational bioinformatic study identifying m6A-related miRNAs as prognostic markers in colorectal cancer using TCGA/GEO datasets. Although it mentions 'randomized' (splitting patients into training/validation sets) and includes a Kaplan-Meier analysis, it is not a clinical trial of a drug intervention. The publication types include 'Randomized Controlled Trial', but this appears to be a misclassification for this type of biomarker study. There is no drug intervention, and it is not a Phase III or definitive randomized trial of a therapeutic agent.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
HPV testing in Polish population-based cervical cancer screening programme (HIPPO project)-study protocol of a randomised healthcare policy trial. PMID 37978452 · BMC Cancer · 2023-Nov-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Postoperative stellate ganglion block to reduce myocardial injury after laparoscopic radical resection for colorectal cancer: protocol for a randomised trial. PMID 37977873 · BMJ Open · 2023-Nov-17 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Pyrotinib versus placebo in combination with trastuzumab and docetaxel as first line treatment in patients with HER2 positive metastatic breast cancer (PHILA): randomised, double blind, multicentre, phase 3 trial. PMID 37973164 · BMJ · 2023-Nov-16 The record is for a Phase 3 randomized trial of a drug combination in human oncology. The deterministic review flagged a missing time-to-event signal, likely due to the empty abstract. However, the title explicitly identifies it as a definitive Phase 3 randomized trial, and such trials are designed with time-to-event primary endpoints (PFS/OS). The publication is a Journal Article, not a protocol-only or review, confirming it is an original result report.
H B
影子组漏检补回 eligiblemodel_adjudicated_eligible needs_review 0 Figure · 0 Panel · risk not_assessed
Fractionated vs single-dose gemtuzumab ozogamicin with determinants of benefit in older patients with AML: the UK NCRI AML18 trial. PMID 37595359 · Blood · 2023-Nov-16 Meets all required criteria: Phase III randomized drug trial in oncology with OS as primary time-to-event endpoint and original results. Phase is inferred from trial name 'AML18' and definitive comparative design in large cohort, consistent with a major cooperative group trial.
B
影子组漏检补回 eligiblemodel_adjudicated_eligible confirmed 1 Figure · 2 Panel · risk visible
Efficacy and safety of Huachansu combined with adjuvant chemotherapy in resected colorectal cancer patients: a prospective, open-label, randomized phase II study. PMID 37966546 · Med Oncol · 2023-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Effect of traditional Chinese medicine combined group psychotherapy on psychological distress management and gut micro-biome regulation for colorectal cancer survivors: a single-arm phase I clinical trial. PMID 37964024 · Support Care Cancer · 2023-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Proton beam radiotherapy versus transarterial chemoembolization for hepatocellular carcinoma: Results of a randomized clinical trial. PMID 37503907 · Cancer · 2023-Nov-15 The study is an oncology RCT with a time-to-event primary endpoint (OS) and reports original results. However, it is excluded because the intervention (proton beam radiotherapy vs. transarterial chemoembolization) does not contain a drug therapy as defined by the cohort criteria.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Ramucirumab beyond progression plus TAS-102 in patients with advanced or metastatic esophagogastric adenocarcinoma, after treatment failure on a ramucirumab-based therapy. PMID 37455496 · Int J Cancer · 2023-Nov-15 The study is a non-randomized, open-label, investigator-initiated pilot trial. It is not a Phase III, IIIb, or Phase II/III randomized trial as required for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Reducing Target Volumes of Intensity Modulated Radiation Therapy After Induction Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma: Long-Term Results of a Prospective, Multicenter, Randomized Trial. PMID 37356553 · Int J Radiat Oncol Biol Phys · 2023-Nov-15 While the record meets most criteria (oncology, human, randomized, time-to-event endpoints, drug intervention, original long-term results), the trial phase is not explicitly stated as Phase III/IIIb or Phase II/III in the provided metadata or abstract. The 'deterministic_review' notes 'phase3_evidence_unclear' and the signals show 'phase3': false and 'phase3_publication_type': false. Without explicit confirmation of a definitive (Phase III) trial, eligibility cannot be established.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
A Surrogate Endpoint for Overall Survival in Locally Advanced and Resectable Esophageal Squamous Cell Carcinoma: A Reanalysis of Data From the NEOCRTEC5010 Trial. PMID 37210047 · Int J Radiat Oncol Biol Phys · 2023-Nov-15 The record is a secondary analysis/reanalysis of the NEOCRTEC5010 trial, not the primary formal result report of the original randomized trial. While it involves a randomized trial, the phase is not confirmed in the provided metadata, and the analysis focuses on surrogate endpoint validation, not the original trial's primary efficacy results.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Every-Other-Day Versus Once-a-Week Urethra-Sparing Prostate Stereotactic Body Radiation Therapy: 5-Year Results of a Randomized Phase 2 Trial. PMID 37001763 · Int J Radiat Oncol Biol Phys · 2023-Nov-15 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Impact of an in-consult patient decision aid on treatment choices and outcomes of management for patients with an endoscopically resected malignant colorectal polyp: a study protocol for a non-randomised clinical phase II study. PMID 37963688 · BMJ Open · 2023-Nov-14 方案论文未报告临床试验结果。
B
仅广召回影子组 excludedprotocol_without_results pending 0 Figure · 0 Panel · risk -
Differential immunomodulatory effects of epirubicin/cyclophosphamide and docetaxel in breast cancer patients. PMID 37957750 · J Exp Clin Cancer Res · 2023-Nov-14 The record reports a randomized, drug-containing trial in human breast cancer, but the abstract does not mention a Phase III/IIIb or Phase II/III design. More critically, the primary outcomes described are immunomodulatory effects (immune cells, cytokines), not a time-to-event efficacy endpoint like OS, PFS, DFS, or HR from a Kaplan-Meier analysis. Therefore, it does not meet the inclusion criteria for a Kaplan-Meier digitization cohort.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Multitarget Stool RNA Test for Colorectal Cancer Screening. PMID 37870871 · JAMA · 2023-Nov-14 干预为非药物单独策略,未满足药物干预要求。
B
仅广召回影子组 excludednon_drug_intervention pending 0 Figure · 0 Panel · risk -
Midostaurin plus daunorubicin or idarubicin for young and older adults with FLT3-mutated AML: a phase 3b trial. PMID 37581981 · Blood Adv · 2023-Nov-14 The record describes a Phase IIIb randomized trial of midostaurin in FLT3-mutated AML with a drug intervention and original results. However, the abstract does not mention a randomized design or a primary/key secondary time-to-event endpoint (OS, PFS, DFS, etc., Kaplan-Meier, or HR); it reports complete remission rates, which are response endpoints, not time-to-event. Therefore, it fails the required criteria for eligibility.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Dostarlimab or pembrolizumab plus chemotherapy in previously untreated metastatic non-squamous non-small cell lung cancer: the randomized PERLA phase II trial. PMID 37951954 · Nat Commun · 2023-Nov-11 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Machine learning methods for accurately predicting survival and guiding treatment in stage I and II hepatocellular carcinoma. PMID 37960763 · Medicine (Baltimore) · 2023-Nov-10 The study is a machine learning predictive model development and validation using a retrospective SEER database cohort, not a formal Phase III/IIIb or Phase II/III randomized controlled trial report of a specific drug intervention. While it includes human, oncology, randomized (for model training/testing), time-to-event (OS), and drug (chemotherapy) elements, it does not meet the core requirement of being a formal trial report of a definitive phase. The 'Randomized Controlled Trial' publication type tag is misleading in this context; the randomization refers to train/test split, not a clinical trial randomization.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Assessing the prognostic impact of prostatic urethra involvement and developing a nomogram for T1 stage bladder cancer. PMID 37950252 · BMC Urol · 2023-Nov-10 The record describes a retrospective, non-randomized prognostic model (nomogram) development study using a registry database (SEER) and a single-center validation cohort. It is not a Phase III/IIIb or Phase II/III randomized controlled trial evaluating a drug intervention.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -
Phase I non-randomized clinical trial of allogeneic natural killer cells infusion in acute myeloid leukemia patients. PMID 37950209 · BMC Cancer · 2023-Nov-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Randomized Phase II Multicenter Trial of Abiraterone Acetate With or Without Cabazitaxel in the Treatment of Metastatic Castration-Resistant Prostate Cancer. PMID 37582240 · J Clin Oncol · 2023-Nov-10 仅有 Phase I/II 证据,未达到确证性随机试验标准。
B
仅广召回影子组 excludedearly_phase_only pending 0 Figure · 0 Panel · risk -
Compliance-Adjusted Estimates of Aspirin Effects Among Older Persons in the ASPREE Randomized Trial. PMID 37552955 · Am J Epidemiol · 2023-Nov-10 The study is a randomized trial of aspirin for primary prevention of events in older adults, not a cancer treatment or prevention trial. While it reports time-to-event endpoints (e.g., disability-free survival, cancer mortality), the intervention is not an oncology drug, and the primary focus is not cancer.
B
仅广召回影子组 excludedmodel_adjudicated_excluded pending 0 Figure · 0 Panel · risk -